On August 1997, AMBI Inc. acquired the entire beneficial interest in Nutrition 21, a limited partnership, ("N21") by way of the acquisition of Selene Systems, Inc. ("Selene"), which is the general partner of N21. On November 2011, the company was acquired again by Phillip and Michael Satow. Nutrition 21 specialized in branded therapeutic nutrition supplements for disease-specific conditions. The Company's first branded product, Diachrome positioned to aid in the dietary management of diabetes and marketed with the support of healthcare professionals. Diachrome is planned for introduction under the Nutrition 21 label in 2003. Primary efficacy claims include improved insulin function and healthy blood glucose levels for people with type 2 diabetes. Nutrition 21 has commissioned its fourth clinical trial to validate Diachrome's efficacy and pharmacoeconomic benefits. The Company was incorporated as Applied Microbiology, Inc. (AMBI) and was initially focused on the development and commercialization of antibacterial technologies for new drugs. Beginning in 1995, Nutrition 21 began to shift its focus to the development and marketing of nutrition products.
